| [1] |
DUAN M, LI Y, LIU J, et al. Transmission routes and patterns of helicobacter pylori[J]. Helicobacter, 2023, 28(1): e12945. doi:10.1111/hel.12945
doi: 10.1111/hel.12945
|
| [2] |
吴新国, 郑汝桦, 常新, 等. 2024年美国胃肠病学院幽门螺杆菌感染治疗最新临床实践指南要点解读[J]. 实用医学杂志, 2025, 41(4): 459-464.
|
| [3] |
WANG F, YAO Z, JIN T, et al. Research progress on Helicobacter pylori infection related neurological diseases[J]. Ageing Res Rev, 2024, 99: 102399. doi:10.1016/j.arr.2024.102399
doi: 10.1016/j.arr.2024.102399
|
| [4] |
MILLER A K, WILLIAMS S M. Helicobacter pylori infection causes both protective and deleterious effects in human health and disease[J]. Genes Immun, 2021, 22(4): 218-226. doi:10.1038/s41435-021-00146-4
doi: 10.1038/s41435-021-00146-4
|
| [5] |
MALFERTHEINER P, MEGRAUD F, ROKKAS T, et al. Management of Helicobacter pylori infection: The Maastricht VI/Florence consensus report[J]. Gut, 2022. doi: 10.1136/gutjnl-2022-327745 . Online ahead of print.
doi: 10.1136/gutjnl-2022-327745
|
| [6] |
中华医学会消化病学分会幽门螺杆菌学组. 第六次全国幽门螺杆菌感染处理共识报告(非根除治疗部分)[J].胃肠病学,2022,27(5):289-304.
|
| [7] |
2022中国幽门螺杆菌感染治疗指南[J]. 胃肠病学, 2022, 27(3): 150-162.
|
| [8] |
临床常用四环素类药物合理应用多学科专家共识编写组, 中华预防医学会医院感染控制分会, 中国药理学会临床药理分会. 临床常用四环素类药物合理应用多学科专家共识[J]. 中华医学杂志, 2023, 103(30): 2281-2296.
|
| [9] |
ASADI A, ABDI M, KOUHSARI E, et al. Minocycline, focus on mechanisms of resistance, antibacterial activity, and clinical effectiveness: Back to the future[J]. J Glob Antimicrob Resist, 2020, 22: 161-174. doi:10.1016/j.jgar.2020.01.022
doi: 10.1016/j.jgar.2020.01.022
|
| [10] |
SUO B, TIAN X, ZHANG H, et al. Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial[J]. Chin Med J (Engl), 2023, 136(8): 933-940. doi:10.1097/cm9.0000000000002629
doi: 10.1097/cm9.0000000000002629
|
| [11] |
YOU S, TANG X, ZHOU J, et al. Minocycline/Amoxicillin-Based Bismuth Quadruple Therapy for Helicobacter pylori Eradication: A Pilot Study[J]. Microorganisms, 2024, 12(3):429. doi:10.3390/microorganisms12030429
doi: 10.3390/microorganisms12030429
|
| [12] |
AL-KURAISHY H M, AL-GAREEB A I, ALQARNI M, et al. Pleiotropic Effects of Tetracyclines in the Management of COVID-19: Emerging Perspectives[J]. Front Pharmacol, 2021, 12: 642822. doi:10.3389/fphar.2021.642822
doi: 10.3389/fphar.2021.642822
|
| [13] |
ZOU L, MEI Z, GUAN T, et al. Underlying mechanisms of the effect of minocycline against Candida albicans biofilms[J]. Exp Ther Med, 2021, 21(5): 413. doi:10.3892/etm.2021.9857
doi: 10.3892/etm.2021.9857
|
| [14] |
TSHIBANGU-KABAMBA E, YAMAOKA Y. Helicobacter pylori infection and antibiotic resistance - From biology to clinical implications[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(9): 613-629. doi:10.1038/s41575-021-00449-x
doi: 10.1038/s41575-021-00449-x
|
| [15] |
王先令, 周国强, 林琳, 等. 伏诺拉生联合阿莫西林、克拉霉素三联七日疗法根除幽门螺杆菌的临床研究[J]. 实用医学杂志, 2022, 38(10): 1271-1275.
|
| [16] |
BAI P, ZHOU L Y, XIAO X M, et al. Susceptibility of Helicobacter pylori to antibiotics in Chinese patients[J]. J Dig Dis, 2015, 16(8): 464-470. doi:10.1111/1751-2980.12271
doi: 10.1111/1751-2980.12271
|
| [17] |
SINGH S, KHANNA D, KALRA S. Minocycline and Doxycycline: More Than Antibiotics[J]. Curr Mol Pharmacol, 2021, 14(6): 1046-1065. doi:10.2174/1874467214666210210122628
doi: 10.2174/1874467214666210210122628
|
| [18] |
HUANG Y, QIU S, GUO Y, et al. Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Real-World Evidence Study[J]. Helicobacter, 2024, 29(5): e13138. doi:10.1111/hel.13138
doi: 10.1111/hel.13138
|
| [19] |
MURAKAMI K, SATO R, OKIMOTO T, et al. Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection[J]. J Gastroenterol Hepatol, 2006, 21(1 Pt 2): 262-267. doi:10.1111/j.1440-1746.2006.04183.x
doi: 10.1111/j.1440-1746.2006.04183.x
|
| [20] |
张灵云, 蓝宇, 王玘, 等. 含米诺环素、甲硝唑的铋剂四联方案根除幽门螺杆菌的临床观察[J]. 实用医学杂志, 2018, 34(16): 2766-2769.
|
| [21] |
SONG Z Q, ZHOU L Y. Esomeprazole, minocycline, metronidazole and bismuth as first-line and second-line regimens for Helicobacter pylori eradication[J]. J Dig Dis, 2016, 17(4): 260-267. doi:10.1111/1751-2980.12334
doi: 10.1111/1751-2980.12334
|